Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 8/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.67 |
| ▸ | PRKDC | P78527 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632465 | 0.85 | CYP1A2 (0.65) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL909747 | 0.85 | CYP1A2 (0.64) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL31061509 | 0.80 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL2149342 | 0.80 | CYP1A1 (0.61) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL31632516 | 0.79 | CYP1A1 (0.58) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL31632237 | 0.78 | CYP1A1 (0.56) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL12556193 | 0.77 | TERT (0.71) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL1647031 | 0.77 | TNKS (0.69) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL30742026 | 0.77 | TNKS (0.69) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E | |
| SCHEMBL30307582 | 0.77 | TNKS (0.69) | CYP1A1CYP1A2CYP1B1PRKDCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| EP-2342188-B1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2342188-B1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010037127-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037127-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP1A1 1724/4885CYP1A2 1857/4885CYP1B1 1112/4885 |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP1A1 1534/4885CYP1A2 1508/4885CYP1B1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.